NEW HUGE RELEASE: “True You Principles & Methods”
A 50-episode Talk Series on how to heal, grow, and relate
Updates on the work of Manitoba’s Enhanced Therapy Institute
Here at Manitoba’s Enhanced Therapy Institute, we have been busy paving the way for MDMA-Assisted Therapy in this province. Here’s a brief overview of what we have been up to.
New York Times agrees with my opinion on why FDA delayed approval of MDMA Assisted Therapy
In recent article, New York Times seems to paint a picture that closely resembles my own understanding of why FDA Assisted Therapy was delayed by the FDA.
Nothing Has Changed About the Healing Power of MDMA-Assisted Therapy
So after years of hype and hope, the FDA did not approve MDMA Assisted Therapy for the treatment of PTSD at this time. This is a tectonic shift in the entire field of psychedelic therapies. Here are some of my reflections on this historic decision.
How Power Trip became its own power trip
A report on the state of the MDMA Therapy orchard
FDA Psychopharmacologic Drug Advisory Committee rejects use of MDMA-Assisted Therapy for PTSD
In a stunning decision, an FDA-appointed advisory committee, comprised of 11 independent experts, rejected MDMA-Assisted Therapy as a treatment for PTSD, voting that the evidence for both its effectiveness and safety is insufficient.
Psychedelic Alpha on June 4th FDA Advisory Meeting
June 4th is fast approaching, with a group of experts scheduled to meet to advise the FDA on whether to approve MDMA-assisted therapy for the treatment of PTSD.
June 4 2024 is an important date for MDMA-Assisted Therapy
The FDA is currently in the final stages of the MDMA-Assisted Therapy approval process, with the decision expected in August 2024. The next stage in the approval process is the meeting of the FDA Advisory Committee on June 4 to review Lykos Therapeutics’ application.
<strong>Will MDMA-Assisted Therapy for PTSD be approved in 2024?</strong>
Below is a reprint of a major news release from MAPS, an organization that was solely responsible for the FDA MDMA-Assisted Therapy research.
MAPS PBC No Longer a Public Benefit Corporation
The Multidisciplinary Association for Psychedelic Studies (MAPS) has been admirably resistant to the pressures of the market economy for a long time. But the capital have won, again, and in a somewhat sad move, MAPS’s pharmaceutical arm, the MAPS Public Benefit Corporation, has now become a conventionally structured pharmacological company called Lykos Pharmaceutical.
